Article
MIF functional polymorphisms are associated with acute GVHD progression and steroid-refractoriness.
Frontiers in immunology - 1 Jan 2025
Aharon Aviran, Avni Batia, Louzoun Daniel, Elias Shlomo, Stepensky Polina, Ram Ron, Zuckerman Tsila, Meza-Romero Roberto, Vandenbark Arthur A, Grisariu Sigal, Benedek Gil
Abstract excerpt
Introduction: Approximately 50% of allogeneic hematopoietic stem cell transplantation (HSCT) Q6 recipients develop graft versus host disease (GVHD). Glucocorticoids (GC) are the first line of treatment for both acute and chronic GVHD. Failure to respond to GC [steroid-refractory (SR)] encompasses a very poor outcome with high mortality. Macrophage migration inhibitory factor (MIF) is released during...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
